Despite the promise of immune checkpoint therapies, treatment-resistant cancers remain a stubborn frontier, making it difficult to predict treatment responsiveness and optimize treatment protocols. A ...
Optimization of Voyager V1 (VV1) oncolytic virus systemic delivery in combination with cemiplimab and ipilimumab in patients with melanoma and non–small cell lung cancer (NSCLC). Background: Merkel ...
CD8 + cytotoxic T lymphocytes (CTLs) serve as central effectors in cancer immunotherapy by directly eliminating tumor cells. However, current clinical therapies face significant limitations. These ...
Randomized phase II trial of gemcitabine, avelumab and carboplatin versus no neoadjuvant therapy preceding surgery for cisplatin-ineligible muscle-invasive urothelial carcinoma (MIUC): SWOG GAP trial ...
Our core provides customized MHC/peptide tetramers for identification of antigen-specific T lymphocytes by flow cytometry. Tetramers and/or their derivatives are provided for research purposes only.
SINGAPORE & SAN DIEGO & OKLAHOMA CITY & AUSTIN, Texas--(BUSINESS WIRE)--ImmunoScape, a pre-clinical biotechnology company focused on the discovery and development of next-generation TCR cell therapies ...
Immunological memory refers to the ability of the immune system to “remember” and respond more rapidly and effectively to pathogens previously encountered. Memory T cells generated during previous ...
MHC-I presents peptides derived from endogenous antigens. Antigen is proteolyzed by the immune proteasome and specific peptides loaded to MHC-I. The resulting MHC-I–peptide complex is transported to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results